Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenue, net:
Core companion animal health	$ 61,502	$ 57,481	$ 55,655
Other vaccines, pharmaceuticals and products	11,303	12,584	9,796
Total revenue, net	72,805	70,065	65,451
Cost of revenue	41,704	40,878	40,659
Gross profit	31,101	29,187	24,792
Operating expenses:
Selling and marketing	18,339	15,167	14,726
Research and development	958	1,650	1,597
General and administrative	9,646	9,121	8,111
Total operating expenses	28,943	25,938	24,434
Operating income (loss)	2,158	3,249	358
Interest and other expense, net	135	(117)	289
Income (loss) before income taxes	2,023	3,366	69
Current tax expense	214	165	61
Deferred tax expense (benefit)	606	1,056	(10)
Total income tax expense (benefit)	820	1,221	51
Net income (loss)	$ 1,203	$ 2,145	$ 18
Basic net income (loss) per share	$ 0.23	$ 0.41	$ 0.00
Diluted net income (loss) per share	$ 0.22	$ 0.40	$ 0.00
Weighted average outstanding shares used to compute basic net income (loss) per share	5,326	5,237	5,220
Weighted average outstanding shares used to compute diluted net income (loss) per share	5,489	5,338	5,254